Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Non-HAP CAM-A ALG-006746 and ALG-006780 induce rapid HBsAg reductions in AAV-HBV mice and have favorable pharmacokinetic profiles

Saturday, June 1, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the promising results of CAM-A ALG-006746 and ALG-006780 in inducing rapid reductions of HBsAg in AAV-HBV mice. These compounds also demonstrate favorable pharmacokinetic profiles, suggesting potential for further development in treating chronic HBV infection. The findings may pave the way for future clinical trials.
Price reaction · baseline $14.75 (2024-05-31 close) · 5 other ALGS headline(s) in the window, move may be shared
day 0 close · peak
+4.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Rapid HBsAg reductions observed in AAV-HBV mice.
  • Favorable pharmacokinetic profiles for CAM-A ALG-006746 and ALG-006780.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What are CAM-A ALG-006746 and ALG-006780?

They are compounds being studied for their effects on HBsAg in chronic HBV infection.

What results were observed in the study?

The study reported rapid reductions of HBsAg in AAV-HBV mice.

What is the significance of pharmacokinetic profiles?

Favorable pharmacokinetic profiles suggest better absorption and efficacy in treatments.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare HBV AAV-HBV CAM-A ALG-006746
Last updated: Jun 1, 2024

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →